Progyny stock hits 52-week high at 37.16 USD By Investing.com
Progyny Inc. (PGNY) stock recently achieved a 52-week high of $37.16, marking a substantial increase of 37.99% over the past year, with further strong gains in recent months. This performance is attributed to increasing demand for its fertility benefits management services and positive market sentiment, with InvestingPro suggesting the stock remains undervalued. The company also reported strong Q3 2026 earnings, surpassing Wall Street expectations, which led to analysts like Citizens and Wells Fargo raising their price targets for PGNY.
Truist Securities maintains Progyny at Buy, raises price target to $42 from $36
Truist Securities has reiterated its "Buy" rating for Progyny (PGNY) and increased its price target from $36 to $42, representing a 16.7% raise. This new price target suggests a 13.1% upside from Progyny's closing price of $37.15 on November 16. The article also lists recent analyst actions from other firms, with price targets ranging from $35 to $38.
Progyny stock hits 52-week high at 37.16 USD By Investing.com
Progyny Inc. (PGNY) stock reached a new 52-week high of $37.16, reflecting significant appreciation over the past year and strong momentum in recent months. This surge is attributed to growing demand for its fertility services and positive market sentiment, with InvestingPro data suggesting the stock remains undervalued. The company recently surpassed Wall Street expectations in its Q3 2026 earnings, leading analysts to raise price targets.
Form 4 Progyny Inc: Geoffrey Clapp (Chief Product Officer) For: 11 November
This article reports on a Form 4 filing for Progyny Inc., specifically noting activity by Geoffrey Clapp, the Chief Product Officer, related to November 11. The article itself is brief, essentially serving as an announcement of the filing without providing further details on the nature of the transaction.
Sold at $36.41 each, 774 Progyny (PGNY) shares leave Clapp holding 58,235 directly.
Geoffrey Clapp, Chief Product Officer of Progyny, Inc. (PGNY), sold 774 shares of common stock at $36.41 per share on November 11, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on August 12, 2026. Following the sale, Clapp directly holds 58,235 shares of Progyny.
Progyny CEO Peter Anevski sells $8.48 million in company stock
Progyny CEO Peter Anevski sold approximately $8.48 million worth of company stock on November 10, 2026, including shares sold under a pre-arranged trading plan and additional shares after exercising vested stock options. This insider sale occurred while Progyny shares were trading near their 52-week high, following a strong third-quarter earnings report and raised full-year guidance, with analysts maintaining positive ratings.
Executive chairman David Schlanger sells Progyny shares worth $1.25M By Investing.com
David J. Schlanger, Executive Chairman of Progyny, Inc., sold 35,392 shares of common stock totaling $1,251,507 on November 10, 2026. This transaction occurred near the stock's 52-week high and followed Schlanger's exercise of options for the same number of shares. The sale was executed under a Rule 10b5-1 trading plan.
Form 4 Progyny Inc: Peter Anevski (Director, CEO) For: 10 November By Investing.com
This article from Investing.com reports on a Form 4 filing for Progyny Inc., indicating that Peter Anevski, who serves as both a Director and CEO, made a transaction on November 10. The article is brief and primarily serves as an announcement of this regulatory filing.
Executive chairman David Schlanger sells Progyny shares worth $1.25M
David J. Schlanger, Executive Chairman of Progyny, Inc. (NASDAQ:PGNY), sold 35,392 shares of common stock for a total of $1,251,507 on November 10, 2026, following the exercise of options. The sale was part of a Rule 10b5-1 trading plan. Progyny recently reported strong third-quarter 2026 earnings, exceeding analyst expectations and leading to increased price targets from Citizens and Wells Fargo.
Form 4 Progyny Inc: David J. Schlanger (Director, Executive Chairman) For: 10 November
This article reports on a Form 4 filing for Progyny Inc., indicating that David J. Schlanger, a Director and Executive Chairman, made a transaction on November 10. The filing, dated November 12, 2026, details insider trading activity for the company (PGNY).
Exercising options at $0.91, Progyny (PGNY) CEO also sells shares.
Progyny, Inc.'s CEO, Peter Anevski, exercised 185,134 stock options at $0.91 per share on November 10, 2026. Concurrently, he sold a total of 236,630 common shares across four transactions at weighted-average prices ranging from $35.6067 to $36.2851, with some sales executed under a Rule 10b5-1 trading plan. Following these transactions, Anevski holds 710,972 common shares and 157,369 stock options.
What Does Progyny’s Falling Multiple Really Say?
Progyny (PGNY) has seen its price-to-earnings multiple decline significantly over the past three years, while its share price has risen. This article explains that the lower multiple does not necessarily mean the stock is cheaper, but rather reflects the company's substantial profit growth that investors were anticipating. Progyny's profit has grown significantly, and its multiple is now above the S&P 500 average.
774 shares are slated for sale by Progyny (PGNY) officer Geoffrey Clapp.
Geoffrey Clapp, an officer at Progyny, Inc. (PGNY), plans to sell 774 common shares valued at $28,181.34, with an approximate sale date of November 11, 2026. These shares were acquired through restricted stock vesting on September 17, 2026, as compensation. The sale plan adoption date was recorded as August 12, 2026.
Progyny executive chairman David Schlanger sells $5.88M in stock By Investing.com
Progyny's executive chairman, David J. Schlanger, sold approximately $5.88 million worth of company stock in early November 2026, following the exercise of stock options. The transactions were executed under a Rule 10b5-1 trading plan. This comes after Progyny reported strong third-quarter earnings, exceeding expectations, and raised its full-year outlook, leading to positive analyst revisions and price target increases.
Progyny CEO Peter Anevski sells $6.18 million in company stock
Progyny CEO Peter Anevski sold approximately $6.18 million worth of company stock in early November 2026, after acquiring shares through stock option exercises. The sales occurred while Progyny's shares were trading near their 52-week high, with the company showing strong growth prospects and recent positive earnings reports. Anevski still holds 762,468 shares of common stock after these transactions.
A trust proposes selling 50,139 Progyny (PGNY) shares under a prearranged trading plan.
A trust known as Anevski 2026 South Dakota NGCG Trust proposes selling 50,139 common shares of Progyny, Inc. (PGNY), valued at approximately $1.8 million. The proposed sale date is November 10, 2026, under a Rule 10b5-1 plan adopted on July 2, 2026. These shares were acquired through restricted stock units, performance stock units, and an employee stock purchase plan between January 1, 2022, and March 3, 2026.
Form 4 Progyny Inc: Peter Anevski (Director, CEO) For: 5 November
This article reports on a Form 4 filing for Progyny Inc., concerning Peter Anevski, who serves as a Director and CEO of the company. The filing pertains to activities on November 5th. Further details of the transaction are not provided in the snippet.
After exercising $0.91 options, Progyny (PGNY) chairman sells 161,208 shares.
Progyny, Inc. Executive Chairman David J. Schlanger recently exercised options for 161,208 shares at $0.91 per share and subsequently sold them at a weighted average price of $35.7263 per share. These transactions, along with a smaller sale of 3,400 shares, were conducted under a Rule 10b5-1 trading plan. The options exercised were fully vested and exercisable.
Form 144 Progyny For: 7 November By Investing.com
This article from Investing.com announces the filing of Form 144 for Progyny (PGNY) on November 7, 2026. The brief piece indicates that Progyny's stock saw a 1.37% increase, and is primarily a news alert for investors interested in SEC filings and stock performance.
Progyny CFO Mark Livingston sells $64,170 in company stock
Progyny's Chief Financial Officer, Mark S. Livingston, sold 2,139 shares of company stock for a total of $64,170 on November 4, 2026. This transaction was part of a pre-established trading plan, leaving him with 70,314 direct shares. The company has shown strong performance, with its stock appreciating significantly since the sale, trading near its 52-week high, and analysts maintaining positive ratings and raising price targets following strong Q3 2026 earnings.
Leerink Partners maintains Progyny at Outperform, raises price target to $38 from $37
Leerink Partners has reiterated its "Outperform" rating for Progyny (PGNY) and increased its price target to $38 from $37, indicating a potential upside of 26.2% from its November 4 closing price. This adjustment aligns with other recent analyst actions, including Wells Fargo and Citizens maintaining "Overweight" and "Market Outperform" ratings respectively, both with a $38 price target. Cantor Fitzgerald also maintained an "Overweight" rating with a $35 target.
Form 4 Progyny Inc: Mark S. Livingston (CFO) For: 4 November By Investing.com
This article reports on a Form 4 filing for Progyny Inc., indicating an insider transaction by Mark S. Livingston, the Chief Financial Officer. The filing pertains to activity on November 4, related to the company's stock, PGNY.
Progyny stock hits 52-week high at 33.19 USD
Progyny Inc. (PGNY) stock recently hit a 52-week high of $33.19, reflecting strong investor confidence and a 67.13% increase over the past year. The fertility benefits management company reported third-quarter 2026 earnings that surpassed expectations and raised its full-year outlook, leading analysts to increase their price targets for PGNY shares. InvestingPro analysis suggests the stock is currently undervalued, with potential for further upside.
Progyny 3Q 2026: Revenue $341.25M, EPS $0.32 — 10-Q Summary
Progyny reported a significant increase in third-quarter 2026 revenue and net income, driven by higher client and covered-life counts. The company's fertility benefits and Progyny Rx segments both contributed to growth, while gross margin improved due to care-management efficiencies and reduced operating expenses. Progyny now serves 607 clients and over 7 million members.
Q3 revenue reaches $341M at Progyny (PGNY) as net income climbs from $13.9M.
Progyny (PGNY) reported a significant increase in its Q3 2026 net income to $26.3 million, up from $13.9 million in the prior year, with revenue climbing to $341 million from $313.3 million. For the first nine months of 2026, total revenue reached $1.02 billion, and net income hit $78.5 million. The company also expanded its client base to 607, covering 7.155 million members, and repurchased 9.68 million shares for $230.9 million during the nine-month period.
An 8,160-share stock grant and 11,370 options go to Progyny (PGNY) general counsel Allison Swartz.
Progyny, Inc. reported that its EVP, GC Allison Swartz received 8,160 restricted stock units and an option award for 11,370 common shares on November 2, 2026. The options have an exercise price of $29.41 per share, and her direct common-stock holdings after the RSU award were 83,976 shares. Both awards vest in stages from March 2, 2027, through March 2, 2029, contingent on her continued service.
Progyny earnings beat, revenue topped estimates
Progyny (NASDAQ: PGNY) reported third-quarter earnings per share of $0.32, surpassing analyst estimates of $0.31. The company's revenue also exceeded expectations, coming in at $341.25 million against a consensus estimate of $340.76 million. Progyny's stock has seen significant growth, rising 7.12% in the last three months and 59.43% over the past year.
Progyny (NASDAQ:PGNY) Stock Jumps on Q3 Earnings Beat and Record Selling Season Outlook
Progyny (NASDAQ:PGNY) reported third-quarter 2026 results with revenue in line with expectations and adjusted earnings well ahead, leading to a significant after-hours stock jump. The company achieved solid growth in revenue and profitability, with lower stock-based compensation and improved gross margin contributing to the bottom line. Management also highlighted a record selling season, securing 1.3 million new covered lives and near 100% client retention for 2027.
Progyny Q3 2026 Earnings Call Transcript
Progyny (NASDAQ: PGNY) reported strong third-quarter 2026 financial results with record revenue and profitability, raising its full-year revenue guidance to $1.365-$1.385 billion. The company achieved significant growth by adding 1.3 million new covered lives and over 85 new clients, alongside near 100% client retention and a 20% upsell rate for the 2027 season. Management emphasized the company's competitive differentiation, scalability, and effective cost containment in a high medical cost inflation environment.
Progyny's Record Selling Season Outshines A Basis-Driven EPS Miss, But Margins Show Little Leverage
Progyny reported a Q3 EPS miss that was largely due to a comparison between GAAP and non-GAAP figures, while revenue slightly beat expectations. The quarter's highlight was a record selling season for 2027, adding 1.3 million new covered lives and over 85 clients, suggesting strong future growth. However, adjusted profit growth relied heavily on share buybacks and lower stock compensation, and margins showed little leverage.
Progyny, Inc. Stock 12‑Month Price Target Raised to $35.33, Implies 17% Upside
According to estimates from 12 analysts, Progyny, Inc.'s average stock price target has increased from $34.42 to $35.33, with forecasts ranging from $30 to $40 per share. Based on the Nov. 4 closing price, this updated target suggests a potential upside of approximately 17%. The consensus rating from the 12 covering analysts remains a "Buy," with 10 Buys, 2 Holds, and 0 Sells.
Progyny, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:PGNY) 2026-11-04
Progyny, Inc. has published its slide deck in conjunction with its Q3 2026 earnings call. The company's earnings call presentation is now available for review, providing insights into their financial results for the quarter. This release is part of Seeking Alpha's ongoing coverage of earnings call transcripts.
Progyny, Inc. Announces Third Quarter 2026 Results
Progyny, Inc. reported record third-quarter 2026 results for revenue, gross profit, Adjusted EBITDA, and net income, alongside significant growth in covered lives and client retention. The company added 1.3 million new covered lives and over 85 new clients, while achieving nearly 100% retention for 2027. Based on these strong results, Progyny has raised the midpoint of its full-year 2026 financial guidance.
Progyny Q2 Earnings Call Highlights
Progyny (PGNY) reported record Q2 2026 revenue, gross profit, and adjusted EBITDA, with revenue increasing 5.3% year-over-year. The company expanded gross margins by 180 basis points and generated over $50 million in operating cash flow. Progyny also repurchased 1.2 million shares for $31.5 million and expects early sales commitments and client retention to position it favorably for the 2027 selling season, maintaining its target of adding 1 million or more new lives.
Progyny (PGNY) Stock Looks About Right On Its 56% Run
Progyny (PGNY) has seen a significant 56.1% share price increase over the past year, prompting questions about whether its current valuation is justified by its earnings. The company's P/E ratio of 28.5x is modestly above the healthcare sector average but below direct peers, which is partially explained by new positive clinical outcomes data from its Menopause and Midlife program. Simply Wall St's analysis suggests the stock is currently valued close to its tailored fair multiple estimate, with some narratives indicating it could be undervalued.
Progyny’s (PGNY) Full-Year Guidance Lowered on Utilization Headwinds
Progyny, Inc. (PGNY) saw its shares detract from performance in Q3 2026 due to softer-than-expected utilization trends and a lowered full-year revenue guidance. The company, which specializes in fertility and family-building benefits management, adjusted its revenue outlook to $1.36–$1.385 billion, down from a previous range of $1.365–$1.405 billion. Despite near-term headwinds, management remains optimistic about the 2027 selling season, citing strong client retention and an attractive valuation.
New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits
A new study by Progyny, presented at the ASRM 2026 Scientific Congress & Expo, revealed that racial and ethnic disparities in fertility treatment initiation persist even among patients with access to fertility benefits. While the time from consultation to a pregnancy-resulting treatment cycle was comparable across groups, significant differences were found in initiation rates and treatment pathways. The findings underscore the need to understand clinical, personal, and other factors influencing treatment decisions beyond benefit access to ensure equitable care.
New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits
A new study by Progyny reveals that racial and ethnic disparities in fertility treatment initiation persist even when patients have access to fertility benefits. While treatment initiation rates were lower for African American/Black, Asian/Pacific Islander, and Other/Mixed race and ethnicity patients compared to White patients, the time from consultation to a pregnancy-resulting treatment cycle was largely comparable across groups. The findings underscore the need to understand other factors influencing treatment decisions beyond benefit access, such as clinical indications, patient preferences, and potential barriers to care.
BlackRock updates its passive Progyny (PGNY) stake, with one iShares fund above 5%.
BlackRock, Inc. has filed an amended ownership report for Progyny, Inc. (PGNY), disclosing a passive stake of 14.7% as of September 30, 2026, representing 11,294,526 shares. The report specifies that BlackRock holds sole voting power over 11,153,536 shares and sole dispositive power over all 11,294,526 shares. Notably, the iShares Core S&P Small-Cap ETF, managed by BlackRock, holds an interest exceeding 5% in Progyny's outstanding common stock.
Precision Trading with Progyny Inc. (PGNY) Risk Zones
This article provides a detailed analysis of Progyny Inc. (PGNY) with strong sentiment supporting an overweight bias and an exceptional 59.9:1 risk-reward setup. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. Key findings indicate robust support levels and resistance targets across near-term, mid-term, and long-term horizons.
New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model
A new study by Progyny, Inc. reveals that over 70% of members in its Menopause and Midlife program experienced significant improvement in menopause symptoms, particularly those who received both personalized coaching and care from menopause-trained providers. The research, detailed in the white paper "Beyond the Hype: Evidence for a Connected Model of Menopause Care," highlights the effectiveness of a connected care model in addressing the growing demand for evidence-based menopause support. This integrated approach, combining education, personalized guidance, and specialized clinical care, resulted in substantial reductions across various symptoms, including hot flashes and sleep disturbance.
Progyny, Inc. Estimates – NASDAQ:PGNY
This article from TradingView provides an overview of Progyny, Inc. (NASDAQ: PGNY) financial data and analyst estimates. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform highlights trends over time for the income statement, balance sheet, and cash flow.
Progyny, Inc. (PGNY) Stock forecasts
Argus has raised its target price for Progyny, Inc. (PGNY) to $31.00, citing the company's specialization in fertility, family building, and women's health benefits solutions. Progyny is a benefits management company with a current stock price of $29.12. The report, published on October 21, 2026, suggests a positive outlook for the healthcare sector company.
What Does Progyny’s Falling Multiple Really Say?
Progyny's price-to-earnings multiple has fallen significantly from 75.6 in mid-2023 to 28.4, making the stock appear cheaper. This drop is partly due to a 27.4% decline in share price, but also a substantial increase in profit and share buybacks. Despite the lower multiple, investors need to consider what growth expectations were priced in previously and how current profit levels compare to past periods of higher multiples.
Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report
Progyny, Inc. (Nasdaq: PGNY) will report its financial results for the third quarter ending September 30, 2026, after market close on Wednesday, November 4, 2026. The company will host a conference call at 4:45 p.m. Eastern Time on the same day to discuss the results. An audio replay and webcast will be available for those unable to attend the live call.
Progyny COO Melissa Cummings sells $52,612 in shares
Progyny COO Melissa Cummings sold 1,879 shares of company stock for $52,612 on October 14, 2026, as part of a pre-established trading plan. Following the sale and tax-related share withholding, Cummings now directly holds 66,496 shares. The company recently reported strong Q2 2026 earnings, exceeded analyst expectations, and secured a new partnership with CalPERS.
Wells Fargo Maintains Progyny(PGNY.US) With Buy Rating, Maintains Target Price $37
Wells Fargo has reaffirmed its Buy rating on Progyny (PGNY.US), while keeping its price target at $37. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Form 4 Progyny Inc: Melissa B. Cummings (COO) For: 14 October
This article reports on a Form 4 filing for Progyny Inc. concerning Melissa B. Cummings, the company's COO, for October 14. The piece briefly mentions the stock symbol PGNY and its performance, but provides no further details about the transaction itself.
Form 4 Progyny Inc: Melissa B. Cummings (COO) For: 14 October
This article reports on a Form 4 filing for Progyny Inc., indicating an insider transaction involving Melissa B. Cummings, the COO, on October 14th. The article is very brief and primarily serves as an announcement of the filing rather than providing detailed analysis of the transaction.
Progyny COO Melissa Cummings sells $52,612 in shares By Investing.com
Melissa Cummings, COO of Progyny, Inc., sold 1,879 shares of the company's common stock for a total of $52,612 on October 14, 2026, as part of a Rule 10b5-1 trading plan. Despite this sale, Progyny's stock has increased by 48% in the past six months, and the company maintains a "GREAT" financial health score according to InvestingPro. Recent news also highlights strong Q2 2026 earnings, increased price targets from analysts, and strategic partnerships.